

## Original Article

# Correlation between Glycated Hemoglobin and Dyslipidemia in Type-2 Diabetes Mellitus

Maqsood Ahmad<sup>1</sup>, Iqra Ijaz<sup>2</sup>, Nadia Rasheed<sup>3</sup>, Muhammad Saeed<sup>4</sup>, Sumbla Ghaznavi<sup>5</sup>, Mohammad Mahmood Asghar Saleemi<sup>6</sup>

<sup>1</sup>Medical Lab Scientist, Dept of Chemical pathology, University of Health Sciences, Lahore

<sup>2</sup>Dept of Morbid Anatomy and Histopathology, University of Health Sciences, Lahore

<sup>3</sup>Senior Research Officer, Dept of Chemical Pathology, University of Health Sciences, Lahore

<sup>4</sup>Medical Lab Scientist, Dept of Pathology, Punjab Institute of Cardiology Lahore

<sup>5</sup>Assistant Professor and HOD Chemical Pathology, University of Health Sciences, Lahore

<sup>6</sup>Additional Medical Superintendent, Jinnah Hospital, Lahore

## Abstract

**Objective:** To evaluate correlation between glycated haemoglobin and dyslipidaemias in patients with type-2 Diabetes Mellitus (DM).

**Patients and Methods:** Participants were selected from out-patient department of Sheikh Zayed Hospital, Lahore and Laboratory analysis was performed at department of chemical pathology, University of Health Sciences, Lahore. Total 60 patients of type-2 DM and 40 age and gender matched controls were included in study. Glycated haemoglobin (HbA<sub>1c</sub>), fasting blood glucose (FBG) and lipid profile was performed after overnight fasting. Control group was labelled as Group-A and patient group was labelled as Group-B. Mean of all parameters from both groups was compared and checked for significance by independent sample t-test and Pearson correlation.

**Results:** There was no significant difference in mean values of all biochemical parameters between both genders, except total cholesterol, which was found higher in females (p-value 0.047). Only 3.3% (n = 02) patients had normal lipid profile, 76.6% (n = 46) had one-abnormal parameter of lipid profile, 28.3% (n = 17) patients had two-abnormal parameter of lipid profile and 58.3% (n = 35) had mixed type of dyslipidemia. HbA<sub>1c</sub> was positively correlated with all parameters of lipid profile except HDL-C, which was negatively correlated.

**Conclusion:** There is positive correlation between level of glycemic control (HbA<sub>1c</sub>) and severity of dyslipidemia in patients of type 2 DM.

**Key Words:** Cardiovascular diseases, Diabetes mellitus type 2, Dyslipidemia, Glycated haemoglobin.

## Introduction

Diabetes mellitus (DM) is cosmopolitan disease of the globe. DM is a group of metabolic disorders characterized by hyperglycemia either due to the lack of insulin secretion, or defects of insulin action or both.<sup>1</sup> Recent reports showed that there were 171 million people in the world with diabetes in year 2000 and this is expected to increase to 366 million by 2030.<sup>2</sup> It is associated with reduced life expectancy, significant morbidity due to specific diabetes related microvascular complications, increased risk of macrovascular complications (ischaemic heart disease, stroke and peripheral vascular disease), and lessened quality of life.

Glycated haemoglobin (HbA<sub>1c</sub>) is usually used as a monitoring tool for measuring glycemic control in DM patients. It gives glycemic control status for last 120 days.<sup>3</sup> HbA<sub>1c</sub> predicts risk for development of diabetic complication in diabetic patients. United Kingdom Prospective Diabetes Study (UKPDS) has revealed that risk of diabetic complications was strongly associated with previous hyperglycemia. Good glycemic control with decreased level of HbA<sub>1c</sub> is likely to reduce risk of complications.<sup>4</sup> Estimated risk of cardiovascular disease (CVD) has shown to be increased by 18% for each 1% increase in absolute HbA<sub>1c</sub> value in diabetics.<sup>5</sup>

The chronic hyperglycemia can damage several body organs due to microvascular and macrovascular complications.<sup>6,7</sup> Macrovascular complications of diabetes include cardiovascular disease (CVD) such as stroke, which is the cause of death in 50% of diabetics.<sup>8,9</sup> On the other hand, microvascular complications of diabetes include diabetic nephropathy, neuropathy, and retinopathy.<sup>10</sup> Cardiovascular risk of diabetes increases further if diabetes is related with dyslipidemia. However, this risk can be reduced by good management and control of both hyperglycemia and dyslipidemia.<sup>11,12</sup>

A few studies have previously tried to find relationship between HbA<sub>1c</sub> levels, fasting blood glucose (FBG) and

### Corresponding Author:

**Maqsood Ahmad**

E-mail: [maqsoodahmad64@yahoo.com](mailto:maqsoodahmad64@yahoo.com)

Received: Received Oct 21, 2016; Accepted Jan 9, 2017

lipid profile. Some of these have shown that all parameters of lipid profile have significant association with glycemic control.<sup>13</sup> On the other hand, some studies do not report significant correlation between glycemic control and parameters of lipid profile.<sup>14</sup> Positive relationship between HbA<sub>1c</sub> and CVD has been demonstrated in non-diabetic subjects even within normal range of HbA<sub>1c</sub>.<sup>15,16</sup>


These controversies motivated us to conduct this study, to find out correlation between glycemic control (HbA<sub>1c</sub>), FBG and different parameters of lipid profile in type 2 diabetic patients coming to out-patients department of endocrinology at Sheikh Zayed Hospital, Lahore.

## Patients and Methods

Prior to the start of study ethical permission was obtained from ethical committee of the Sheikh Zayed Hospital, Lahore. Total 60 patients of type 2 DM for > 05 years with overnight fasting were recruited from Sheikh Zayed Hospital, Lahore. Patients with renal disease, thyroidal illness, history of alcohol intake and improper fasting were excluded from study. Total 40 age and gender matched controls without history of any acute or chronic illness were also included. 02ml fasting blood samples were obtained after signing informed consent from all participants for the measurement of HbA<sub>1c</sub>, FBG and Lipid profile. HbA<sub>1c</sub>, FBG and Lipid Profile were performed on Monza Chemistry Analyzer by using Randox reagent kits. The instrument was properly calibrated and quality control (QC) levels were also run along with patient sample. HbA<sub>1c</sub> was performed by affinity Chromatography technique. Statistical analysis was performed by using IBM – SPSS version 21.0. Independent sample t-test (2-tailed) was used to compare mean of all parameters. Pearson's correlation test was done to evaluate correlations of HbA<sub>1c</sub> with all other parameters. All values of different parameters were expressed using conventional units. p-value ≤ 0.05 was considered statistically significant.

## Results

Among sixty patients, 66% (n = 40) were females and remaining 34% (n = 20) were males. Out of forty controls, 47.5% (n = 19) were males and 52.5% (n = 21) were females. Mean age for patient group was 51.17±6.85 years (male=52.85±7.12 years and female= 50.32±6.63 years) and for controls mean age was 42.82±13.66 years (male =45.53±12.69 years and female = 40.38±14.35 years). The frequency of dyslipidemia in our study population was 98%. Only 02% showed normal lipid profile components. Most common type of dyslipidemia was increased levels of low density lipoprotein cholesterol (LDL-C) (68.3%) followed by hyper-triglyceridemia (55%), hyper-cholesterolemia (46.7%) and decreased levels of high density lipoprotein cholesterol (HDL-C) (Figure-1).



**Figure-1: Frequency of Dyslipidemia in diabetic patients**

In patient group (group-B) mean values of TC 42.33mg/dl, VLDL-C 11.89mg/dl, LDL-C 93.49mg/dl, Triglyceride 58.29mg/dl, HbA<sub>1c</sub> 4.56% and FBG 89.52mg/dl were higher than control group (Group-A).

Mean age for males in total study population was 2.52 years higher than females. Mean levels (mg/dl) of VLDL-C, HDL-C, LDL-C, TG, FBG and HbA<sub>1c</sub> (%) were relatively higher in females (Table-1).

**Table-1: Comparison of lipid profile parameters and glycemic indices between group-A and group- B**

Parameter	Group-A (n=40) Mean±SD	Group-B (n=60) Mean±SD	p- Value
TC (mg/dl)	158.30±19.01	200.63±54.60	0.000*
VLDL-C (mg/dl)	24.33±3.90	36.22±20.13	0.000*
HDL-C (mg/dl)	83.43±18.55	48.28±15.88	0.000*
LDL-C (mg/dl)	24.33±3.89	117.82±52.09	0.000*
TG (mg/dl)	121.78±15.92	180.07±90.50	0.000*
HbA <sub>1c</sub> (%)	4.49±0.50	9.05±1.86	0.000*
FBG (mg/dl)	87.85±6.11	177.27±65.73	0.000*

\*p-value≤0.05 is considered statistically significant

We divided patient group (Group – B) further in to two sub-groups as good glycemic control (GGC) group and poor glycemic control (PGC) group. In GGC group patients had level of HbA<sub>1c</sub> < 7% and in PGC patients had level of HbA<sub>1c</sub> > 7%. We compared mean levels of lipid profile between these two groups. Mean difference of FBG was

found 53.0 mg/dl higher in group PGC and this was found statistically significant (Table-2).

<b>Table-2: Biochemical Parameters categorize on the basis of HbA<sub>1c</sub></b>			
<b>Parameters</b>	<b>HbA<sub>1c</sub>&lt; 7 (GGC) (n=10)</b>	<b>HbA<sub>1c</sub>&gt; 7 (PGC) (n=50)</b>	<b>p-Value</b>
Age (Years)	52.90±7.97	50.82±6.64	0.385
TC (mg/dL)	211.40±49.36	198.48±55.80	0.449
VLDL-C(mg/dL)	32.80±13.88	36.90±21.20	0.561
HDL-C (mg/dL)	53.60±23.35	47.22±14.01	0.423
LDL-C (mg/dL)	124.80±46.43	116.42±53.48	0.646
TG-C (mg/dL)	175.90±67.32	180.90±95.00	0.875
FBG-C (mg/dL)	133.10±34.60	186.10±67.12	0.001*

\*p-value ≤0.05 is considered statistically significant, GGC: Good glycemic control, PGC: Poor glycemic control  
HbA<sub>1c</sub> was positively correlated with all components of lipid profile except HDL-C which showed negative correlation. FBG showed significant positive correlation with HbA<sub>1c</sub> (Table-3).

<b>Table 3: Correlation between HbA<sub>1c</sub> and all biochemical parameters (n = 60)</b>		
<b>Parameters</b>	<b>Correlation r-value</b>	<b>p-value</b>
TC (mg/dL)	0.082	0.532
VLDL-C(mg/dL)	0.244	0.061
HDL-C(mg/dL)	-0.058	0.658
LDL-C(mg/dL)	0.029	0.826
TG (mg/dL)	0.173	0.187
FBG (mg/dL)	0.396	0.002*

\*p-value ≤ 0.05 is considered statistically significant

## Discussion

Despite many strategies for diagnosis and monitoring of DM, still this is a major challenge for public health around the globe. In conditions like uncontrolled DM the proportion of glycosylated haemoglobin increases substantially. This glycosylation of haemoglobin is result of non-enzymatic binding of haemoglobin A molecules with glucose which occurs only once during the life of single red blood cell. The levels of HbA<sub>1c</sub> reflect the degree of glycemic control for last 120 days. So this is being used for diagnosis and monitoring diabetic control as well. The diabetic dyslipidemia is connected with raised levels of triglycerides, LDL-C and decreased HDL-C.<sup>17</sup>

In our study we evaluated correlation of HbA<sub>1c</sub> with dyslipidemia. In Group-B 98.0% patients showed significant

dyslipidemia. High LDL-C is most common followed by hyper-triglyceridemia, Hyper-cholesterolemia and Low LDL-C.

Al-alawi et al in 2014 reported high prevalence of hypercholesterolemia, hypertriglyceridemia, high LDL-C and low HDL-C. They revealed that increase LDL-C level is more frequent type of dyslipidemia.<sup>18</sup> It is well known that high LDL-C and low HDL-C levels are risk factors for development of cardiovascular diseases. Insulin effects the liver apolipoprotein production which is responsible for enzymatic activity of lipoprotein lipase and cholesterol esters transport protein. All these factors collectively cause dyslipidemia in DM.<sup>19</sup>

Hyper triglyceridemia can be due to alteration of lipoprotein in type- 2 DM. It is caused by hyperglycemia, insulin resistance which results in overproduction of VLDL-C, defective clearance of VLDL-C, decreased activity of lipoprotein lipase and decreased production of apolipoprotein B. Consumption of VLDL is altered which ultimately results in atherosclerosis. In type-2 DM, hyperglycemia increases the activity of hepatic lipase which leads to enhanced clearance of HDL-C while impaired catabolism of VLDL-C which causes decreased production of HDL-C.<sup>20</sup>

In present study, diabetic patients (n = 60) were divided into two groups as GGC group which included only 10 patients and PGC group which contained 50 patients. Severity of dyslipidemia was higher in patients with increased levels of Glycated hemoglobin (HbA<sub>1c</sub> >7%). Elevated HbA<sub>1c</sub> and dyslipidemia are sovereign risk factors of cardiovascular diseases. Through improvement in glycemic control, one can markedly diminish risk of cardiovascular events in diabetics. It has been assessed that reducing HbA<sub>1c</sub> level by 0.2% could lower mortality by 10%.<sup>6</sup> Khan et al reported that impact of glycemic control is directly related to the severity of dyslipidemia.<sup>21</sup>

The dyslipidaemia in diabetic is frequent because insulin resistance or deficiency affects vital enzymes and lipid metabolism.<sup>22,23</sup> It affects the following processes: apoprotein production, regulation of lipoprotein lipase, action of cholesteryl ester, transfer proteins and hepatic and peripheral actions of insulin.<sup>22</sup> It has been suggested that composition of lipid particles in diabetic dyslipidaemia is more atherogenic than other types of dyslipidaemia. This means that even normal lipid concentrations might be more atherogenic in diabetic than in nondiabetic people.<sup>22,24,25</sup>

Pearson correlation was observed between HbA<sub>1c</sub> and other components of lipid profile and FBG. A significant positive correlation was seen with FBG. Our findings were strongly matched with previous literature reports.<sup>26,27</sup> We also found positive but non-significant correlations between HbA<sub>1c</sub> and cholesterol, triglycerides, LDL-C and VLDL-C in type-2 diabetic patients. HDL-C was found negatively correlated with HbA<sub>1c</sub>. Previously many researchers have reported the

importance of HbA<sub>1c</sub> for controlling dyslipidemia in patients with type-2 DM.<sup>28,29</sup>

## Conclusion

Positive but non-significant correlation is found between glycemic control and severity of dyslipidemia in patients with type-2 DM. Thus by maintaining a good glycemic control, risk for the development of dyslipidemia and cardiac diseases can be reduced. Further studies should be conducted on a larger scale to significantly explore the role of HbA<sub>1c</sub> in the development of dyslipidemia in type-2 Diabetic patients.

## Acknowledgment

We appreciate support from **Syed Mohsin Raza Bokhari** for statistical analysis of data.

## Conflict of Interest

This study has no conflict of interest as declared by any author.

## References

- Goldberg IJ. Diabetic dyslipidemia: statins versus fibrates in the treatment of diabetic dyslipidemia. Paper presented at: Symposium, program and abstracts of the 6st scientific sessions of the American Diabetic Association; 2001 June 22-26; Philadelphia, Pennsylvania.
- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. *Diabetes care*. 2004;27(5):1047-53.
- Delamater AM. Clinical use of hemoglobin A1c to improve diabetes management. *Clin Diabetes*. 2006;24(1):6-8.
- Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321(7258):405-12.
- Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. *Ann Intern Med*. 2004;141(6):421-31.
- Genuth S, Alberti KG, Bennett P, Buse J, DeFronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care*. 2003;26(11):3160-67.
- UK Prospective Diabetes Study (UKPDS); VIII Study design, progress and performance. *Diabetol*. 1991; 34(12):877-90.
- World Health Organization. Diabetes, Fact sheet [internet]. Nov 2016. Available from :<http://www.who.int/mediacentre/factsheets/fs312/en/>
- Glycosylated Haemoglobin, HbA<sub>1c</sub>. Nov 2013. Available from: <https://clinlabnavigator.com/test-interpretations/haemoglobina1c.html?letter=h>
- Fowler MJ. Microvascular and macrovascular complications of diabetes. *Clin Diabetes*. 2008; 26(2):77-82.
- Haffner SM, Lehto S, Rönkämaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*. 1998;339(4):229-234.
- Windler E. What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome? *Atheroscler Suppl*. 2005;6(3):11-14.
- Ramona G, Ioan C, Simona T, Luminia P, Simona G, Lavinia M. Relationship between glycosylated hemoglobin and lipid metabolism in patients with type 2 diabetes. *Studia Universitatis Vasile Goldiş Seria Ştiinţele Vieţii*. 2011;21(2):313-8.
- Yan Z, Liu Y, Huang H. Association of glycosylated hemoglobin level with lipid ratio and individual lipids in type 2 diabetic patients. *Asian Pac J Trop Med*. 2012;5(6):469-71.
- Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective investigation into cancer in Norfolk. *Ann Intern Med*. 2004;141(6):413-20.
- Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. *Clin Chem*. 1973;19(5):476-82.
- Hongbing Xiao. Method and composition for determining high density lipoprotein cholesterol. Chinese Patent. 2002; CN1379235A.
- Al-Alawi. Serum lipid profile and glycated hemoglobin status in Omani patients with type2 diabetes mellitus attending a primary care polyclinic. *Biomed Res India*. 2014;25(2):161-6.
- Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. *J Lipid Res*. 1996;37(4):693-707.
- Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. *Diabetes Care*. 2005;28(3):514-20.
- Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA<sub>1c</sub> predicts dyslipidaemia. *Clin Exp Med*. 2007;7(1):24-9.
- Elmasri H, Ahmed A. Patterns of lipid changes among type 2 diabetes patients in Sudan. *East Mediterr Health J*. 2008;4(2):314-4.
- Dixit AK, Dey R, Suresh A, Chaudhuri S, Panda AK, Mitra A, et al. The prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda Hospital. *J Diabetes Metab Disord*. 2014;13(1):58.
- Necht LE, Zaccaro D, Espeland MA, Karter AJ, O'Leary DH, Haffner SM. Diabetes and progression of carotid atherosclerosis the insulin resistance atherosclerosis study. *Arterioscler Thromb Vasc Biol*. 2003;23(6):1035-41.
- Taskinen MR. Diabetic dyslipidemia. *Atheroscler Suppl*. 2002;3(1):47-51.
- Rosediani M, Azidah AK, Mafauzy M. Correlation between fasting plasma glucose, post prandial glucose and glycated haemoglobin and fructosamine. *Med J Malaysia*. 2006;61(1):67-7.
- Ito C, Maeda R, Ishida S, Sasaki H, Harada H. Correlation among fasting plasma glucose, two hour plasma glucose levels in OGTT and HbA<sub>1c</sub>. *Diabetes Res Clin Pract*. 2000;50:225-30.
- Faulkner MS, Chao WH, Kamath SK, Quinn L, Fritsch C, Maggiore JA, et al. Total homocysteine, diet, and lipid profiles in type 1 and type 2 diabetic and non diabetic adolescents. *J Cardiovasc Nurs*. 2006;21(1):47-55.
- Chan WB, Tong PC, Chow CC, So WY, Ng MC, Ma RC, et al. Triglyceride predicts cardiovascular mortality and its relationship with glycaemia and obesity in Chinese type 2 diabetic patients. *Diabetes Metab Res Rev*. 2005;21(2):183-8.

### Authorship Contribution:

**Author 1,3:** Conception, Synthesis and Planning of the research

**Author 2,6:** Active participation in active methodology

**Author 4,5:** Interpretation, analysis and discussion